BACKGROUND/AIM: Head and neck squamous cell carcinoma affects nearly 500,000 people annually. Augmenting PPARγ functional activation is linked with multiple anti-carcinogenic processes in aerodigestive cell lines and animal models. PPARγ/RXRα heterodimers may be key partners in this activation.
MATERIALS AND METHODS: CA 9-22 and NA cell lines were treated with the PPARγ agonist ciglitazone and/or the RXRα agonist 9-cis-retinoic acid. PPARγ functional activation, cellular proliferation, apoptosis activity, and phenotype were subsequently analyzed.
RESULTS: Ciglitazone and 9-cis-retinoic acid independently activated PPARγ and down-regulated the carcinogenic phenotype in vitro. Combination treatment significantly augmented these effects, further decreasing proliferation (p<0.0001), and increasing PPARγ functional activation (p<0.0001), apoptosis (p<0.05), and adipocyte differentiation markers (p<0.0001).
CONCLUSION: The efficacy of the combination of ciglitazone and 9-cis-retinoic acid afforded lowering treatment concentrations while maintaining desired therapeutic outcomes, optimistically supporting the feasibility and practicality of this novel treatment option.
|Original language||English (US)|
|Number of pages||10|
|State||Published - Jun 1 2020|
Bibliographical noteFunding Information:
The Authors would like to thank Donna Seabloom for comments on the manuscript. This work was funded by the Lion’s 5M Hearing Center Grant (Minnesota) and P30 CA77598-07 (NCI/NIH).
© 2020 International Institute of Anticancer Research. All rights reserved.
- 9-cis-retinoic acid
- Neck squamous carcinoma
- PPAR gamma/metabolism
- Survival Rate
- Mouth Neoplasms/drug therapy
PubMed: MeSH publication types
- Journal Article